» Articles » PMID: 36358762

Medical Device Advances in the Treatment of Glioblastoma

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Nov 11
PMID 36358762
Authors
Affiliations
Soon will be listed here.
Abstract

Despite decades of research and the growing emergence of new treatment modalities, Glioblastoma (GBM) frustratingly remains an incurable brain cancer with largely stagnant 5-year survival outcomes of around 5%. Historically, a significant challenge has been the effective delivery of anti-cancer treatment. This review aims to summarize key innovations in the field of medical devices, developed either to improve the delivery of existing treatments, for example that of chemo-radiotherapy, or provide novel treatments using devices, such as sonodynamic therapy, thermotherapy and electric field therapy. It will highlight current as well as emerging device technologies, non-invasive versus invasive approaches, and by doing so provide a detailed summary of evidence from clinical studies and trials undertaken to date. Potential limitations and current challenges are discussed whilst also highlighting the exciting potential of this developing field. It is hoped that this review will serve as a useful primer for clinicians, scientists, and engineers in the field, united by a shared goal to translate medical device innovations to help improve treatment outcomes for patients with this devastating disease.

Citing Articles

Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies.

Dhiman A, Rana D, Benival D, Garkhal K Ther Deliv. 2024; 16(1):87-115.

PMID: 39445563 PMC: 11703381. DOI: 10.1080/20415990.2024.2415281.


Emerging and Biological Concepts in Pediatric High-Grade Gliomas.

Yoel A, Adjumain S, Liang Y, Daniel P, Firestein R, Tsui V Cells. 2024; 13(17.

PMID: 39273062 PMC: 11394548. DOI: 10.3390/cells13171492.


Directionally non-rotating electric field therapy delivered through implanted electrodes as a glioblastoma treatment platform: A proof-of-principle study.

Ma J, Singh S, Li M, Seelig D, Molnar G, Wong E Neurooncol Adv. 2024; 6(1):vdae121.

PMID: 39156619 PMC: 11327618. DOI: 10.1093/noajnl/vdae121.


Magnetic Hyperthermia Therapy for High-Grade Glioma: A State-of-the-Art Review.

Rodriguez B, Rivera D, Zhang J, Brown C, Young T, Williams T Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543086 PMC: 10976112. DOI: 10.3390/ph17030300.


Autophagy Inhibition with Chloroquine Increased Pro-Apoptotic Potential of New Aziridine-Hydrazide Hydrazone Derivatives against Glioblastoma Cells.

Witusik-Perkowska M, Glowacka P, Pieczonka A, Swiderska E, Pudlarz A, Rachwalski M Cells. 2023; 12(14).

PMID: 37508570 PMC: 10378024. DOI: 10.3390/cells12141906.


References
1.
Vitaz T, Warnke P, Tabar V, Gutin P . Brachytherapy for brain tumors. J Neurooncol. 2005; 73(1):71-86. DOI: 10.1007/s11060-004-2352-4. View

2.
Gatto L, Di Nunno V, Franceschi E, Tosoni A, Bartolini S, Brandes A . Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. Drugs. 2022; 82(5):491-510. DOI: 10.1007/s40265-022-01702-6. View

3.
Zou M, Zhang L, Wang J, Wang Q, Gao J, Fan P . Investigation on interaction and sonodynamic damage of fluorescein derivants to bovine serum albumin (BSA) under ultrasonic irradiation. Spectrochim Acta A Mol Biomol Spectrosc. 2013; 110:364-76. DOI: 10.1016/j.saa.2013.03.073. View

4.
Carpentier A, Canney M, Vignot A, Reina V, Beccaria K, Horodyckid C . Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med. 2016; 8(343):343re2. DOI: 10.1126/scitranslmed.aaf6086. View

5.
Park S, Kim M, Jung H, Chang W, Choi H, Rachmilevitch I . One-Year Outcome of Multiple Blood-Brain Barrier Disruptions With Temozolomide for the Treatment of Glioblastoma. Front Oncol. 2020; 10:1663. PMC: 7511634. DOI: 10.3389/fonc.2020.01663. View